Kyverna Therapeutics, Inc.
KYTX
$1.83
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -37.49M | -34.49M | -28.80M | -26.69M | -20.67M |
| Total Depreciation and Amortization | 563.00K | 558.00K | 530.00K | 482.00K | 462.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -169.00K | 1.19M | -310.00K | 2.52M | 633.00K |
| Change in Net Operating Assets | 34.00K | 5.25M | 4.41M | -1.84M | 1.01M |
| Cash from Operations | -37.06M | -27.49M | -24.18M | -25.53M | -18.56M |
| Capital Expenditure | -532.00K | -102.00K | -1.03M | -543.00K | -334.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.75M | 778.00K | -66.89M | -122.34M | 32.02M |
| Cash from Investing | 29.22M | 676.00K | -67.92M | -122.88M | 31.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -247.00K | -242.00K | -236.00K | -231.00K | -219.00K |
| Issuance of Common Stock | 32.00K | 90.00K | 73.00K | 341.24M | 275.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -406.00K | -2.96M | -1.49M |
| Cash from Financing | -215.00K | -152.00K | -569.00K | 338.05M | -1.43M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.05M | -26.97M | -92.67M | 189.65M | 11.68M |